Zacks Investment Research lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a research note published on Tuesday.

According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “

Several other equities analysts have also recently weighed in on ANIP. Canaccord Genuity set a $77.00 price objective on ANI Pharmaceuticals and gave the company a buy rating in a report on Friday, December 29th. ValuEngine cut ANI Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, December 20th. BidaskClub cut ANI Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, December 21st. Finally, TheStreet raised ANI Pharmaceuticals from a c+ rating to a b rating in a research report on Thursday, November 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. ANI Pharmaceuticals presently has a consensus rating of Buy and an average target price of $71.00.

ANI Pharmaceuticals (NASDAQ:ANIP) opened at $69.41 on Tuesday. ANI Pharmaceuticals has a 1-year low of $42.23 and a 1-year high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $843.79, a PE ratio of 21.61 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business had revenue of $48.16 million for the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter in the previous year, the business posted $1.09 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 25.0% on a year-over-year basis. analysts forecast that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Thrivent Financial For Lutherans raised its position in ANI Pharmaceuticals by 7.1% in the 2nd quarter. Thrivent Financial For Lutherans now owns 4,840 shares of the specialty pharmaceutical company’s stock valued at $227,000 after buying an additional 320 shares during the last quarter. Ameriprise Financial Inc. raised its position in ANI Pharmaceuticals by 0.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 54,205 shares of the specialty pharmaceutical company’s stock valued at $2,536,000 after buying an additional 340 shares during the last quarter. Dana Investment Advisors Inc. raised its position in ANI Pharmaceuticals by 0.8% in the 2nd quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock valued at $1,999,000 after buying an additional 341 shares during the last quarter. ETRADE Capital Management LLC raised its position in ANI Pharmaceuticals by 5.2% in the 2nd quarter. ETRADE Capital Management LLC now owns 12,990 shares of the specialty pharmaceutical company’s stock valued at $608,000 after buying an additional 640 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in ANI Pharmaceuticals by 44.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 664 shares during the last quarter. 55.05% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/ani-pharmaceuticals-anip-downgraded-by-zacks-investment-research-to-hold/1797179.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.